arrow
R

Raed Alroughani

Amiri Hospital
H指数:46
被引数:8,244

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How patients with neuromyelitis optica spectrum disease accumulate disability

视神经脊髓炎谱系疾病患者如何累积残疾

2026-10-080
PRE
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

在复发缓解型多发性硬化中,针对临床静息期MRI病灶的治疗升级

Brain
IF11.7
2026-07-240
OAAI
Insights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programs

多国真实世界中克拉屈滨片剂依从性的见解:来自患者支持项目的结果

2026-03-280
PRE
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry

抗CD20疗法与S1P受体调节剂在迟发性多发性硬化中的比较疗效:来自MSBase注册研究的真实世界证据

2026-03-260
PRE
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry

多发性硬化疾病 modifying therapies 之间水平切换的实效性:MSBase 注册数据库的回顾性分析

2025-12-230
PRE
Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: an MSBase Registry Sub-Study

奥法美南在复发型多发性硬化中的真实世界有效性:一项MSBase登记研究的子研究

2025-11-250
OAAI
Disease course after pregnancy in women with progressive multiple sclerosis symptoms

妊娠后进展性多发性硬化症状女性的疾病病程

2025-09-200
OA
Persistent progression independent of relapse activity in multiple sclerosis

多发性硬化中与复发活动无关的持续性进展

2025-08-210
OAAI
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

基于真实世界常规临床数据的个性化联邦学习在预测多发性硬化致残进展中的应用

2025-07-240
OAAI
Consensus guidelines on the diagnosis and management of myasthenia gravis by the Saudi Arabia Neuromuscular and Electrodiagnostic Medicine and neuromuscular specialists from the Gulf Cooperation Council region

沙特阿拉伯神经肌肉与电诊断医学学会及海湾合作委员会地区神经肌肉专家制定的肌无力症诊断和管理共识指南

2025-06-270
OA
Role of Immune Reconstitution Therapy with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in Older Patients

克拉屈滨片免疫重建疗法在老年复发型多发性硬化管理中的作用

2025-05-170
OA
Explainable time-to-progression predictions in multiple sclerosis

多发性硬化症可解释的进展时间预测

2025-05-010
PRE
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

一年治疗反应预测复发缓解型多发性硬化患者后续5年的疾病进程

2025-02-010
OAAI
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
2024-11-012
OAAI
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
2024-09-040
PRE
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical Practice
2024-08-030
OAAI
Safety and effectiveness of disease-modifying therapies after switching from natalizumab
2024-07-260
PRE